Clinical trials: Muscle Atrophy
Motor Neuron Disease
A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.
The COMMEND Study will assess the safety and effectiveness of FLX-787 in men and women with Motor Neuron Disease [including Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS) or Progressive Muscular Atrophy…
- Trial name
- NCT03196375
- Testing
- FLX-787-ODT (orally disintegrating tablet)
- Where
- 35 sites in United States
- Volunteers
- 54 people
- Sponsor
- Flex Pharma, Inc.
Muscle Wasting, Non Small Cell Lung Cancer
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if the investigational drug GTx-024 can help subjects with non-small cell lung cancer increase physical function and maintain or gain muscle, also called "lean body mass".
- Trial name
- NCT01355484
- Testing
- GTx-024
- Where
- 27 sites in United States
- Volunteers
- 321 people
- Sponsor
- GTx
Muscle Atrophy, Hypodynamia
Safety Study of HPP593 in Subjects During and After Limb Immobilization
This is a safety and tolerability study investigating the effect of HPP593 in healthy volunteers during and after limb immobilization.
- Trial name
- NCT01524406
- Testing
- HPP593
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- High Point Pharmaceuticals, LLC.
Muscle Loss
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers
Single center, randomized, single dose study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of ACE-031 in healthy postmenopausal volunteers
- Trial name
- NCT00755638
- Testing
- ACE-031
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA